Alkermes (ALKS) Competitors $26.52 -0.45 (-1.67%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$27.20 +0.68 (+2.56%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALKS vs. ABEO, MEDP, OMCL, AMN, UTHR, INCY, NBIX, BMRN, EXAS, and EXELShould you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), and Exelixis (EXEL). These companies are all part of the "medical" sector. Alkermes vs. Its Competitors Abeona Therapeutics Medpace Omnicell AMN Healthcare Services United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Exelixis Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment. Which has more volatility & risk, ABEO or ALKS? Abeona Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Does the media prefer ABEO or ALKS? In the previous week, Alkermes had 22 more articles in the media than Abeona Therapeutics. MarketBeat recorded 24 mentions for Alkermes and 2 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 1.77 beat Alkermes' score of 0.72 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alkermes 9 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts recommend ABEO or ALKS? Abeona Therapeutics presently has a consensus target price of $19.50, suggesting a potential upside of 240.91%. Alkermes has a consensus target price of $41.85, suggesting a potential upside of 57.79%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92 Do insiders & institutionals hold more shares of ABEO or ALKS? 80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 6.9% of Abeona Therapeutics shares are held by insiders. Comparatively, 4.4% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher earnings & valuation, ABEO or ALKS? Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$400K733.29-$63.73M$0.708.17Alkermes$1.56B2.81$367.07M$2.0812.75 Is ABEO or ALKS more profitable? Alkermes has a net margin of 23.15% compared to Abeona Therapeutics' net margin of 0.00%. Abeona Therapeutics' return on equity of 89.05% beat Alkermes' return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A 89.05% 45.64% Alkermes 23.15%24.86%17.14% SummaryAlkermes beats Abeona Therapeutics on 9 of the 17 factors compared between the two stocks. Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALKS vs. The Competition Export to ExcelMetricAlkermesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.45B$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio12.7521.2475.0426.40Price / Sales2.81421.35506.03174.59Price / Cash10.1744.4425.8129.91Price / Book2.939.6413.426.28Net Income$367.07M-$53.20M$3.29B$270.38M7 Day Performance-4.78%0.07%0.09%1.89%1 Month Performance-8.71%4.27%4.56%6.01%1 Year Performance-4.71%9.62%74.87%25.26% Alkermes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALKSAlkermes4.556 of 5 stars$26.52-1.7%$41.85+57.8%-4.1%$4.45B$1.56B12.751,800ABEOAbeona Therapeutics4.1219 of 5 stars$6.70-2.8%$19.50+191.0%+2.5%$343.58M$3.50M9.5790Positive NewsMEDPMedpace4.3092 of 5 stars$492.09+1.0%$412.73-16.1%+41.2%$13.82B$2.11B36.595,900Positive NewsOMCLOmnicell4.0668 of 5 stars$32.33+0.7%$46.71+44.5%-25.3%$1.48B$1.11B64.663,670Positive NewsAMNAMN Healthcare Services4.6387 of 5 stars$20.97+0.6%$28.25+34.7%-61.4%$803.61M$2.98B-2.702,968Positive NewsShort Interest ↓UTHRUnited Therapeutics4.7769 of 5 stars$394.62-1.5%$429.62+8.9%+18.9%$17.80B$2.88B15.401,305Positive NewsINCYIncyte4.7369 of 5 stars$86.56-0.1%$82.53-4.7%+30.8%$16.90B$4.24B19.672,617Positive NewsAnalyst DowngradeShort Interest ↓NBIXNeurocrine Biosciences4.7589 of 5 stars$143.80-0.2%$160.00+11.3%+14.9%$14.26B$2.36B42.541,800Positive NewsBMRNBioMarin Pharmaceutical4.9383 of 5 stars$56.38-2.4%$92.04+63.3%-37.4%$10.83B$2.85B16.733,040Positive NewsAnalyst UpgradeShort Interest ↑EXASExact Sciences4.7762 of 5 stars$53.89+0.1%$67.05+24.4%-18.5%$10.20B$2.76B-9.927,000Short Interest ↓Analyst RevisionEXELExelixis4.6479 of 5 stars$37.69-0.5%$44.06+16.9%+47.4%$10.15B$2.17B18.121,147Positive NewsAnalyst Downgrade Related Companies and Tools Related Companies Abeona Therapeutics Alternatives Medpace Alternatives Omnicell Alternatives AMN Healthcare Services Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Exelixis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALKS) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
